Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 5/20 | 0.50 |
| ▸ | RARB | P10826 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | ACACA | Q13085 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11969670 | 0.88 | ACACB (0.65) | ACACBLMNAALDH1A1PLK1L3MBTL1 | |
| SCHEMBL16933650 | 0.86 | KDM4E (0.47) | RARBLMNAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL15577827 | 0.85 | KDM4E (0.52) | RARBLMNAALDH1A1PPARGPPARD | |
| SCHEMBL7753233 | 0.82 | NQO1 (0.52) | LMNAALDH1A1PLK1SMN1; SMN2 | |
| SCHEMBL28560657 | 0.80 | SMN1; SMN2 (0.50) | LMNAALDH1A1PLK1SMN1; SMN2 | |
| SCHEMBL4065254 | 0.80 | ELANE (0.55) | ACACBRARBLMNAALDH1A1PLK1 | |
| SCHEMBL15579354 | 0.78 | PRKAB2 (0.47) | LMNAALDH1A1PPARGPPARDPPARA | |
| SCHEMBL15579259 | 0.78 | PRKAB2 (0.49) | LMNAALDH1A1PPARGPPARDPPARA | |
| SCHEMBL12001074 | 0.78 | ACACB (0.80) | ACACBALDH1A1PLK1ACACASMN1; SMN2 | |
| SCHEMBL9152649 | 0.77 | CYP3A4 (0.63) | ACACBRARBALDH1A1PLK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214782-A1 | New compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| WO-2012032014-A1 | ETHYNE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214782-A1 | New compounds, pharmaceutical compositions and uses thereof | ABCG2, PGA5, PDE6G | ACACB 2257/4885RARB 2663/4885LMNA 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.